Sponsor of the Day:
Jerkmate
https://www.businessinsider.es/tecnologia/novartis-saca-chequera-2-000-millones-por-una-biotec-con-un-revolucionario-tratamiento-contra-las-alergias_6951538_0.html
Novartis pagará hasta 1.730 millones por la biotecnológica Excellergy
Mar 27, 2026 - La farmacéutica suiza Novartis ha alcanzado un acuerdo para la adquisición de la empresa biotecnológica estadounidense Excellergy por hasta 1.730 millones de...
millones por lahasta 1novartis730excellergy
https://www.novartis.com/node/667886/printable/print
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation...
inc buildingnext generationnovartisagreesacquire
https://www.biospace.com/deals/novartis-keeps-deals-coming-with-2b-excellergy-takeover
Novartis Keeps Deals Coming With $2B Excellergy Takeover - BioSpace
Mar 27, 2026 - The Excellergy acquisition will complement Novartis’ existing allergy profile, anchored by the IgE blocker Xolair that in February 2024 was approved to treat...
novartiskeepsdealscoming2b
https://www.biopharmadive.com/news/novartis-excellergy-allergy-drugs-deal-xolair/815956/
Novartis targets Xolair successor in buyout of startup Excellergy | BioPharma Dive
Worth up to $2 billion, the deal is centered around a drug that could lead to faster and more complete control of allergic conditions than Novartis and Roche’s...
biopharma divenovartistargetssuccessorbuyout